litlas
Log inCreate account

Anna C. Pavlick

Active 2005–2025

Also published as
Anna C Pavlick
89
Papers
21,032
Citations
65
h-index
89
i10-index

Citations

Citations per year for Anna C. Pavlick2001: 1 citations2006: 2 citations2007: 15 citations2008: 42 citations2009: 50 citations2010: 67 citations2011: 91 citations2012: 189 citations2013: 274 citations2014: 299 citations2015: 353 citations2016: 413 citations2017: 473 citations2018: 426 citations2019: 1,035 citations2020: 1,061 citations2021: 920 citations2022: 815 citations2023: 603 citations2024: 790 citations2025: 379 citations2026: 2 citations2002–2005: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,358 citing papers, 29.6% of this breakdownChina: 1,103 citing papers, 9.7% of this breakdownGermany: 654 citing papers, 5.8% of this breakdownItaly: 638 citing papers, 5.6% of this breakdownUnited Kingdom: 556 citing papers, 4.9% of this breakdownFrance: 549 citing papers, 4.8% of this breakdownAustralia: 498 citing papers, 4.4% of this breakdownSpain: 357 citing papers, 3.1% of this breakdownNetherlands: 338 citing papers, 3% of this breakdownCanada: 327 citing papers, 2.9% of this breakdownSwitzerland: 305 citing papers, 2.7% of this breakdownJapan: 261 citing papers, 2.3% of this breakdown
0%29.6%Other 21.2%

Institutions

Fields

  • Medicine58.6%
  • Biochemistry, Genetics and Molecular Biology28.6%
  • Immunology and Microbiology9.5%
  • Computer Science0.8%
  • Engineering0.7%
  • Neuroscience0.5%
  • Other1.3%

Topics

  • Cancer Immunotherapy and Biomarkers14.5%
  • Immunotherapy and Immune Responses7.4%
  • Melanoma and MAPK Pathways7.1%
  • CAR-T cell therapy research6.1%
  • Cutaneous Melanoma Detection and Management4.8%
  • Immune Cell Function and Interaction3%
  • Other57.1%

Coauthors

All papers

Open in search
  1. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

    Authors: Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani, Karl D. Lewis, Theresa Medina, Harriet M. Kluger, Sajeve Thomas, Evidio Domingo‐Musibay, Anna C. Pavlick, Eric D. Whitman, Salvador Martín‐Algarra, Pippa Corrie, Brendan D. Curti, Judit Oláh, Jose Lutzky, Jeffrey S. Weber, James Larkin, Wen Shi, Toshimi Takamura, Madan Jagasia, Harry Qin, Xiao Wu, Cécile Chartier, Friedrich Graf Finckenstein, Maria Fardis, John M. Kirkwood, Jason Chesney - Journal of Clinical Oncology 2021 cited by 410

  2. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

    Authors: Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Linda M. Rollin, Christine E. Horak, Paul Gagnier, Jedd D. Wolchok, F. Stephen Hodi - New England Journal of Medicine 2015 cited by 2,763

  3. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

    Authors: Hussein A. Tawbi, Peter Forsyth, Alain P. Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos, Nikhil I. Khushalani, Karl D. Lewis, Christopher D. Lao, Michael A. Postow, Michael B. Atkins, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Reena Thomas, Ahmad A. Tarhini, Anna C. Pavlick, Joel Jiang, Alexandre Avila, Sheena Demelo, Kim Margolin - New England Journal of Medicine 2018 cited by 1,321

  4. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study

    Authors: Hussein A Tawbi, Peter A Forsyth, F Stephen Hodi, Alain P Algazi, Omid Hamid, Christopher D Lao, Stergios J Moschos, Michael B Atkins, Karl Lewis, Michael A Postow, Reena P Thomas, John Glaspy, Sekwon Jang, Nikhil I Khushalani, Anna C Pavlick, Marc S Ernstoff, David A Reardon, Ragini Kudchadkar, Ahmad Tarhini, Caroline Chung, Corey Ritchings, Piyush Durani, Margarita Askelson, Igor Puzanov, Kim A Margolin - The Lancet Oncology 2021 cited by 322

  5. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma

    Authors: Scott J. Rodig, Daniel Gusenleitner, Donald Jackson, Evisa Gjini, Anita Giobbie‐Hurder, Chelsea Jin, Han Chang, Scott B. Lovitch, Christine E. Horak, Jeffrey S. Weber, Jason L. Weirather, Jedd D. Wolchok, Michael A. Postow, Anna C. Pavlick, Jason Chesney, F. Stephen Hodi - Science Translational Medicine 2018 cited by 584

  6. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Authors: Antoni Ribas, Igor Puzanov, Reinhard Dummer, Dirk Schadendorf, Omid Hamid, Caroline Robert, F. Stephen Hodi, Jacob Schachter, Anna C. Pavlick, Karl D. Lewis, Lee D. Cranmer, Christian U. Blank, Steven O’Day, Paolo A. Ascierto, April K.S. Salama, Kim Margolin, Carmen Loquai, Thomas Eigentler, Tara C. Gangadhar, Matteo S. Carlino, Sanjiv S. Agarwala, Stergios J. Moschos, Jeffrey A. Sosman, Simone M. Goldinger, Ronnie Shapira‐Frommer, René González, John M. Kirkwood, Jedd D. Wolchok, Alexander M.M. Eggermont, Xiaoyun Li, Wei Zhou, Adriane M Zernhelt, Joy Lis, Scot Ebbinghaus, Sunyu Kang, Adil Daud - The Lancet Oncology 2015 cited by 1,564

  7. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

    Authors: F. Stephen Hodi, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann, David F. McDermott, Gerald P. Linette, Nicolás Meyer, Jeffrey K. Giguere, Sanjiv S. Agarwala, Montaser Shaheen, Marc S. Ernstoff, David R. Minor, April K.S. Salama, Matthew H. Taylor, Patrick A. Ott, Christine E. Horak, Paul Gagnier, Joel Jiang, Jedd D. Wolchok, Michael A. Postow - The Lancet Oncology 2016 cited by 980

  8. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

    Authors: Brandilyn A. Peters, Melissa Wilson, Una Moran, Anna C. Pavlick, Allison Izsak, Todd Wechter, Jeffrey S. Weber, Iman Osman, Jiyoung Ahn - Genome Medicine 2019 cited by 278

  9. Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma

    Authors: Paul Johannet, Nicolas Coudray, Douglas M. Donnelly, George Jour, Irineu Illa-Bochaca, Yuhe Xia, Douglas B. Johnson, Lee Wheless, James R. Patrinely, Sofia Nomikou, David L. Rimm, Anna C. Pavlick, Jeffrey S. Weber, Judy Zhong, Aristotelis Tsirigos, Iman Osman - Clinical Cancer Research 2020 cited by 183

  10. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Authors: Jeffrey A. Sosman, Kevin B. Kim, Lynn M. Schuchter, René González, Anna C. Pavlick, Jeffrey S. Weber, Grant A. McArthur, Thomas E. Hutson, Stergios J. Moschos, Keith T. Flaherty, Peter Hersey, Richard Kefford, Donald P. Lawrence, Igor Puzanov, Karl D. Lewis, Ravi K. Amaravadi, Bartosz Chmielowski, H. Jeffrey Lawrence, Yu Shyr, Fei Ye, Jiang Li, K. B. Nolop, Richard J. Lee, Andrew K. Joe, Antoni Ribas - New England Journal of Medicine 2012 cited by 2,148

  11. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial

    Authors: Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Kevin B. Kim, Tobias Arkenau, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford - The Lancet 2012 cited by 933

  12. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

    Authors: Danny Rischin, Michael R. Migden, Annette M. Lim, Chrysalyne D. Schmults, Nikhil I. Khushalani, Brett Hughes, Dirk Schadendorf, Lara Dunn, Leonel F. Hernandez‐Aya, Anne Lynn S. Chang, Badri Modi, Axel Hauschild, Claas Ulrich, Thomas Eigentler, B. Stein, Anna C. Pavlick, J.L. Geiger, Ralf Gutzmer, Murad Alam, Emmanuel Chiebuka Okoye, Melissa Mathias, Vladimir Janković, Elizabeth Stankevich, Jocelyn Booth, Siyu Li, Israel Lowy, Matthew G. Fury, Alexander Guminski - Journal for ImmunoTherapy of Cancer 2020 cited by 175

  13. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival

    Authors: Dusan Bogunovic, David O’Neill, Ilana Belitskaya‐Lévy, Vladimir Vacic, Yi-Lo Yu, Sylvia Adams, Farbod Darvishian, Russell S. Berman, Richard L. Shapiro, Anna C. Pavlick, Stefano Lonardi, Jiří Zavadil, Iman Osman, Nina Bhardwaj - National Academy of Sciences, Proceedings of the National Academy of Sciences 2009 cited by 381

  14. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

    Authors: Suzanne Leijen, Robin M.J.M. van Geel, Anna C. Pavlick, Raoul Tibes, Lee Rosen, Albiruni Ryan Abdul Razak, Raymond W. Lam, Tim Demuth, Shelonitda Rose, Mark A. Lee, Tomoko Freshwater, Stuart D. Shumway, Li Liang, Amit M. Oza, Jan H.M. Schellens, Geoffrey I. Shapiro - Journal of Clinical Oncology 2016 cited by 269

  15. The State of Melanoma: Emergent Challenges and Opportunities

    Authors: Michael B. Atkins, Clara Curiel‐Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre‐Ghiso, Marı́a S. Soengas, Ashani T. Weeraratna, Keith T. Flaherty, Meenhard Herlyn, Jeffrey A. Sosman, Hussein A. Tawbi, Anna C. Pavlick, Pamela B. Cassidy, Sunandana Chandra, Paul B. Chapman, Adil Daud, Zeynep Eroglu, Laura K. Ferris, Bernard A. Fox, Jeffrey E. Gershenwald, Geoffrey T. Gibney, Douglas Grossman, Brent A. Hanks, Douglas Hanniford, Eva Hernando, Joanne Jeter, Douglas B. Johnson, Samir N. Khleif, John M. Kirkwood, Sancy A. Leachman, Darren Mays, Kelly C. Nelson, Vernon K. Sondak, Ryan J. Sullivan, Glenn Merlino - Clinical Cancer Research 2021 cited by 108

  16. Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma

    Authors: Drew Rasco, Theresa Medina, Pippa Corrie, Anna C. Pavlick, Mark R. Middleton, Paul Lorigan, Chris J. Hebert, Ruth Plummer, James Larkin, Sanjiv S. Agarwala, Adil Daud, Jiaheng Qiu, Viviana Bozón, Michelle Kneissl, Elly Barry, Anthony J. Olszanski - Cancer Chemotherapy and Pharmacology 2023 cited by 40

  17. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

    Authors: Nina Bhardwaj, Philip Friedlander, Anna C. Pavlick, Marc S. Ernstoff, Brian Gastman, Brent A. Hanks, Brendan D. Curti, Mark R. Albertini, Jason J. Luke, Ana-Belén Blázquez, Sreekumar Balan, Davide Bedognetti, Joseph Beechem, Andrea Crocker, Leonard D’Amico, Patrick Danaher, Thomas A. Davis, Thomas Hawthorne, Bruce W. Hess, Tibor Keler, Lisa Lundgren, Chihiro Morishima, Nirasha Ramchurren, Darawan Rinchai, Andres Μ. Salazar, Bob Salim, Elad Sharon, Laura Vitale, Ena Wang, Sarah Warren, Michael Yellin, Mary L. Disis, Martin A. Cheever, Steven P. Fling - Nature Cancer 2020 cited by 126

  18. Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma

    Authors: Mykhaylo Usyk, Abhishek Pandey, Richard B. Hayes, Una Moran, Anna C. Pavlick, Iman Osman, Jeffrey S. Weber, Jiyoung Ahn - Genome Medicine 2021 cited by 70

  19. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

    Authors: Hussein A. Tawbi, Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid, Michael B. Atkins, Karl D. Lewis, Reena Thomas, John A. Glaspy, Sekwon Jang, Alain P. Algazi, Nikhil I. Khushalani, Michael A. Postow, Anna C. Pavlick, Marc S. Ernstoff, David A. Reardon, Igor Puzanov, Ragini R. Kudchadkar, Ahmad A. Tarhini, Anne Sumbul, Jasmine I. Rizzo, Kim Margolin - Neuro-Oncology 2021 cited by 125

  20. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

    Authors: Anna C. Pavlick, Ana-Belén Blázquez, Marcia Meseck, Michael Lattanzi, Patrick A. Ott, Thomas U. Marron, Rose Marie Holman, John Mandeli, Andres Μ. Salazar, Christopher B. McClain, Gustavo Giménez, Sreekumar Balan, Sacha Gnjatic, Rachel Lubong Sabado, Nina Bhardwaj - Cancer Immunology Research 2019 cited by 73

  21. Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

    Authors: Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis - Journal of Clinical Oncology 2012 cited by 477

  22. A phase 2, randomized study of SB‐485232, rhIL‐18, in patients with previously untreated metastatic melanoma

    Authors: Ahmad A. Tarhini, Michael Millward, Paul N. Mainwaring, Richard Kefford, T. Logan, Anna C. Pavlick, Steven J. Kathman, Kevin Laubscher, Mohammed M. Dar, John M. Kirkwood - Cancer 2009 cited by 121

  23. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma

    Authors: Omid Hamid, Igor Puzanov, Reinhard Dummer, Jacob Schachter, Adil Daud, Dirk Schadendorf, Christian U. Blank, Lee D. Cranmer, Caroline Robert, Anna C. Pavlick, René González, F. Stephen Hodi, Paolo A. Ascierto, April K.S. Salama, Kim Margolin, Tara C. Gangadhar, Ziwen Wei, Scot Ebbinghaus, Nageatte Ibrahim, Antoni Ribas - European Journal of Cancer 2017 cited by 180

  24. A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

    Authors: Shailender Bhatia, Anna C. Pavlick, Peter D. Boasberg, John A. Thompson, George Mulligan, Michael D. Pickard, Hélène M. Faessel, Bruce J. Dezube, Omid Hamid - Investigational New Drugs 2016 cited by 112